Vaxxinity company info

What does Vaxxinity do?
Vaxxinity (NASDAQ:VAXX) is a biotechnology firm focused on revolutionizing the approach to immunotherapy and vaccines. Their portfolio spans various projects aimed at tackling significant health challenges, including chronic diseases and infectious ailments. The core objective of Vaxxinity is to develop accessible, efficient vaccine technologies that can offer broad protection and therapeutic benefits to the global population. Their innovative approach seeks to harness the body's immune response in new ways, potentially transforming the treatment landscape for conditions that currently have limited options. With a keen eye on groundbreaking research and development, Vaxxinity aims to lead advances in the field, striving for solutions that can achieve wide-reaching impact on public health.
Vaxxinity company media
Company Snapshot

Is Vaxxinity a public or private company?

key
Ownership
Public

How many people does Vaxxinity employ?

people
Employees
87

What sector is Vaxxinity in?

pie chart
Sector
Health Care

Where is the head office for Vaxxinity?

location pin
Head Office
Dallas, United States

What year was Vaxxinity founded?

founded flag
Year Founded
2014
What does Vaxxinity specialise in?
/Protein Multi-antigen /CONVAX-19 Vaccine /Alzheimer's Vaccine /Parkinson's Treatment /Proimmune Therapeutics /Neurological Disorders

What are the products and/or services of Vaxxinity?

Overview of Vaxxinity offerings
Development of a therapeutic vaccine for chronic neurological conditions such as Alzheimer's disease, focusing on reducing amyloid plaques and slowing cognitive decline.
Creating a prophylactic vaccine aimed at preventing COVID-19 with a focus on accessibility and ease of distribution globally.
Working on a therapeutic vaccine for Parkinson's disease, targeting alpha-synuclein aggregates to halt or slow the progression of neurological symptoms.
Developing a novel therapeutic vaccine intended for the treatment of migraine, aiming to reduce the frequency and severity of migraine episodes.
Innovating in the field of hypercholesterolemia with a vaccine designed to reduce LDL cholesterol levels, potentially offering an alternative to daily medication.
Expanding into therapeutic vaccines for cardiometabolic diseases, aiming at preventing conditions such as atherosclerosis by targeting underlying inflammatory processes.

Who is in the executive team of Vaxxinity?

Vaxxinity leadership team
  • Mr. Louis Garfield Reese IV
    Mr. Louis Garfield Reese IV
    Co-Founder & Executive Chairman of the Board
  • Ms. Mei Mei Hu J.D.
    Ms. Mei Mei Hu J.D.
    CEO & Director
  • Mr. Jason  Pesile CPA, M.B.A.
    Mr. Jason Pesile CPA, M.B.A.
    Chief Accounting Officer
  • Dr. Jean-Cosme  Dodart Ph.D.
    Dr. Jean-Cosme Dodart Ph.D.
    Chief Scientific Officer
  • Ms. Sumita  Ray J.D.
    Ms. Sumita Ray J.D.
    Chief Legal & Administrative Officer
  • Mr. Jon  Harrison
    Mr. Jon Harrison
    Chief Government Officer
  • Mr. Mark  Joinnides MSE
    Mr. Mark Joinnides MSE
    Chief of Staff
  • Ms. Amy B. Fix M.B.A., M.S., R.A.C.
    Ms. Amy B. Fix M.B.A., M.S., R.A.C.
    Head of Regulatory